Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
Tewari KS, Sill MW, Coleman RL, Aghajanian C, Mannel R, DiSilvestro PA, Powell M, Randall LM, Farley J, Rubin SC, Monk BJ. Tewari KS, et al. Among authors: rubin sc. Gynecol Oncol. 2020 Oct;159(1):79-87. doi: 10.1016/j.ygyno.2020.07.015. Epub 2020 Jul 26. Gynecol Oncol. 2020. PMID: 32723679 Free PMC article. Clinical Trial.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Coleman RL, et al. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. N Engl J Med. 2019. PMID: 31722153 Free PMC article. Clinical Trial.
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. Coleman RL, et al. Among authors: rubin sc. Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24. Gynecol Oncol. 2015. PMID: 25818403 Free PMC article. Clinical Trial.
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W; Gynecologic Oncology Group. Aghajanian C, et al. Among authors: rubin sc. Gynecol Oncol. 2009 Nov;115(2):215-20. doi: 10.1016/j.ygyno.2009.07.023. Epub 2009 Aug 26. Gynecol Oncol. 2009. PMID: 19712963 Clinical Trial.
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. Morgan MA, et al. Among authors: rubin sc. Gynecol Oncol. 2011 May 1;121(2):264-8. doi: 10.1016/j.ygyno.2010.12.358. Epub 2011 Feb 1. Gynecol Oncol. 2011. PMID: 21277623 Free PMC article. Clinical Trial.
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Behbakht K, et al. Among authors: rubin sc. Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12. Gynecol Oncol. 2011. PMID: 21752435 Free PMC article. Clinical Trial.
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM. Dizon DS, et al. Among authors: rubin sc. Gynecol Oncol. 2011 Nov;123(2):182-6. doi: 10.1016/j.ygyno.2011.07.016. Epub 2011 Aug 5. Gynecol Oncol. 2011. PMID: 21820161 Free PMC article. Clinical Trial.
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM. McMeekin DS, et al. Among authors: rubin sc. Gynecol Oncol. 2012 Nov;127(2):356-61. doi: 10.1016/j.ygyno.2012.07.095. Epub 2012 Jul 14. Gynecol Oncol. 2012. PMID: 22796461 Clinical Trial.
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Coleman RL, et al. Among authors: rubin sc. Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21. Lancet Oncol. 2017. PMID: 28438473 Free PMC article. Clinical Trial.
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA. Eskander RN, et al. Among authors: rubin sc. Gynecol Oncol. 2018 Jun;149(3):525-530. doi: 10.1016/j.ygyno.2018.03.043. Epub 2018 Mar 15. Gynecol Oncol. 2018. PMID: 29550184 Free PMC article. Clinical Trial.
240 results